Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 1 1

Status

Completed 2Withdrawn 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 3

Conditions

Carcinoma, Hepatocellular 202Carcinoma, Renal Cell 68Liver Neoplasms 61Neoplasms 53Neoplasm Metastasis 34Leukemia, Myeloid, Acute 34Carcinoma, Non-Small-Cell Lung 32Breast Neoplasms 29Melanoma 24Kidney Neoplasms 21Pancreatic Neoplasms 16Brain Neoplasms 15Sarcoma 14Prostatic Neoplasms 14Lung Neoplasms 14Recurrence 13Glioblastoma 13Thyroid Neoplasms 11Colorectal Neoplasms 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Carcinoma 10Urinary Bladder Neoplasms 8Rectal Neoplasms 8Ovarian Neoplasms 8Myelodysplastic Syndromes 8Multiple Myeloma 8Gliosarcoma 8Stomach Neoplasms 7Colonic Neoplasms 7Unspecified Adult Solid Tumor, Protocol Specific 6

Interventions

Sorafenib 3pazopanib 2Sunitinib 2verubulin 1trifluridine tipiracil drug combination 1irinotecan sucrosofate 1eribulin 1Valproic Acid 1Temozolomide 1Sirolimus 1Irinotecan 1Interleukin-27 1Hydralazine 1Erlotinib Hydrochloride 1Azurin 1Arsenic Trioxide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Refractory Solid Tumors × Sorafenib × Clear all
NCT02691780 2019-12-30

Study to Evaluate the Safety and Efficacy of Sorafenib, in Subject With Refractory Solid Tumors

Samsung Medical Center

Phase NA Withdrawn
Other solid neoplasm

Refractory Solid Tumors

NCT02450149 2017-03-13

Single-arm Study to Evaluate the Safety and Efficacy of Sorafenib, in Subjects With BRAF Mutation Refractory Solid Tumors

Samsung Medical Center

Phase NA Completed
1 enrolled
Other solid neoplasm

Refractory Solid Tumors

NCT00759928 2014-07-02

PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors

SCRI Development Innovations, LLC

Phase 1 Completed
48 enrolled
Other solid neoplasm

Refractory Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡